life scienc tool diagnost
manag
manag meet takeaway host investor meet cfo
robert marshal ir director mark kinarney boston manag
reiter guidanc target call revenu growth ep
midpoint vs consensu emphas
sustain defin momentum revenu walk
away meet increment construct defin growth
prospect well lnth pipelin busi develop
opportun make chang estim
lift ep stronger outer year
revenu profit growth trajectori pt
ep higher view
defin pipelin updat flagship defin continu boast
share us ampl runway remain sub-optimal contrast agent
us market penetr estimate address market
opportun expand indic applic microbubbl
technolog manag express optim exist pipelin
defin rt
commerci lmi flurpiridaz repres promis
longer term opportun meanwhil deemphas potenti threat
defin gener entrant near term advantag manufactur
estimate lvef
busi develop focu recent disclos partnership
cerevast continu activ pursu opportun therapeut
adjac focu deal and/or partnership accret
ep within reason time horizon will increas net leverag
current level judici use capit
head manufactur posit well target diversif
opportun method remain thought maintain core
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lantheu global diagnost compani manufactur
medic imag agent associ product focu
cardiovascular well therapeut area
price may rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky target assum signific
acceler defin product pipelin product
approv sooner expect success share gain despit
competit healthi end market growth
grey sky target assum main
associ near-term expiri neg impact sale pipelin
product delay signific share loss increas
 close
takeaway manag
guidanc call revenu million consensu
million ep consensu note also
previous offer quarterli guidanc point sale growth rang
annual rang ep reflect
latest suppli disrupt ntp began april impact technelit
sale lap new competit xenon entrant curium
meanwhil estim defin double-digit continu rise penetr across
sub-optimal echo market
importantli ansto one three supplier along ire
ntp receiv regulatori approv initi product new moli process facil
april expect new facil help mitig potenti futur suppli issu
begin face difficult y/i technelit comp due million
opportunist sale ansto howev technelit comp eas ntp
plant shut june mid-decemb less opportunist sale
xenon still hold domin market share posit expect growth
across product line stabil
defin updat manag deemphas upcom expir defin
composit matter patent june note natur expir
equival brand drug patent cliff sever reason first hatch waxman
act enabl request stay defend defin patent second
manufactur defin complex even replic new entrant would
requir strong technic manufactur expertis commerci execut abl
sell larg hospit effect consist commerci sale process
also involv sell hospit administr doctor and/or technician
complex scale
momentum us defin continu intern sale
defin sale expect meaning growth driver near term
echo market less penetr ou rel us competitor bracco base
itali maintain domin posit said expect ou sale continu
grow albeit low base remind defin known lumin europ
lost momentum europ separ bristol myer squibb
previous reli bmi intern salesforc earli
expand footprint itali portug spain largest intern market
canada australia
manufactur updat intern invest develop manufactur capabl
billerica campu help instil investor confid defin abil
sustain growth view invest could yield better profit profil
defin futur perhap importantli manag note develop
capabl mitig suppli risk jubil hollistersti current sole
sourc manufactur defin
potenti pipelin catalyst manag express optim exist pipelin
defin rt lvef initi closest commerci lmi
flurpiridaz repres promis longer term opportun
regard defin rt manag note room temperatur formul could
facilit partnership opportun similar recent agreement cerevast
room temperatur formul enabl util defin anywher ultrasound
deploy drive enhanc applic therapeut diagnost area
note manag view recent commot regard competit entrant
realist view like year defin rt slate
batch defin rt begin stabil assess
step commerci launch expect point
also reiter estim lvef opportun could doubl defin
address market two parallel phase clinic trial on-going lvef repres
expand indic defin would remov sub-optimal indic
potenti lead protocol includ defin up-front rather sub-optimal
echo identifi physician particular lvef could add valu heart
failur valv diseas chemotherapi patient
regard lmi highlight signific risk stratif capabl
patient consider implant given mani patient across varieti
therapeut area compli recommend surgeri view lmi
help physician commun danger patent could drive greater
complianc continu work fda defin special protocol
assess phase clinic trial
updat version defin store room temperatur produc product qualif batch
gather stabil data prepar regulatori submiss februari manag note defin rt may
commerci avail assum posit fda review approv
lantheu note clinic trial began june track target complet date nda file
commerci launch ge respons clinic trial commerci note trial go well
juli joint press releas announc launch phase trial evalu
efficaci flurpiridaz inject agent use detect coronari arteri diseas cad potenti substitut intracoronari
angiogram potenti improv cad detect reduc radiat exposur previous note believ
potenti particularli valuabl difficult-to-imag patient
remind announc joint collabor april receiv million
payment up-front million regulatori sale mileston payment addit double-digit royalti us sale
singl digit royalti intern sale also option co-promot us first plan
patient enrol june
success complet special protocol assess lvef indic defin initi two parallel clinic
trial remain on-going note studi oper site enrol patient enrol
expect complet expens expect pick complet lantheu plan file
supplement nda commerci could occur earli trial expect drive expens
base analysi medic claim databas manag believ lvef indic would doubl address echo
patient popul believ potenti increas util microbubbl therapeut diagnost applic
includ left ventricular eject fraction indic defin could enabl clinician detect certain diseas
condit identifi decreas pump heart
manag work fda special protocol assess sinc phase clinic trial evalu
efficaci lmi pet agent hope prove first-in-class diagnost tool detect ischem heart
failur patient
march lantheu note phase ii clinic trial shown lmi yield compar estim cardiac
sympathet innerv favor kinet altern hed use current
lantheu report double-cran commun product delay relat chines fda approv defin
lantheu anticip partner double-cran would submit import drug licens double-cran respons
commerci execut china pay lantheu set amount vial sold
double-cran respons clinic trial chines fda complet enrol cardiac kidney liver
pharmacokinet studi
leadership updat remind made sever key hire includ
name robert marshal cfo etienn montagut svp corpor develop
august john bolla svp technic oper may see
emphas chang made help guid toward path leverag
increasingli diversifi portfolio drive consist top-line growth supplement
focu oper effici interestingli highlight etienn montagut skillset
experi part flurpiridaz licens agreement
negoti employe
addit search chief commerci offic remain on-going ceo mari
ann heino current fulfil respons remind previous fill
role take ceo role fill john
bolla promot svp technic oper march
forecast revenu grow million reflect continu
momentum defin rel flat growth technelit
result latest suppli disrupt declin product ebitda
margin declin bp manufactur invest greater cost
relat on-going lvef trial broader pipelin progress ep
increas
forecast revenu increas million sustain doubl digit
growth defin modest rise technelit await greater
visibl suppli disrupt ebitda margin declin bp intern
invest manufactur partial off-set favor mix
defin becom larger proport overal sale ep increas
compani mention price
